BioNap
Long/short equity

Newly Nasdaq-Listed Immune Pharma Offers Big Upside

On August 14, 2014, Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) announced financial results for the second quarter 2014. For the quarter, the company reported no revenues with a net loss of $0.4 million, or $0.03 per share. Net loss for the quarter included $2.0 million in G&A expenses and $1.0 million in R&D expenses. The company reported non-operating income of $3.3 million, mainly due to a decrease in the value of the derivative warrants issued in March 2014.

Immune exited the second quarter 2014 with $3.2 million in cash and cash equivalents. We remind investors that in April 2014, Immune entered into a three-year, $5.0 million revolving line of credit with an existing stockholder, who is related to a member...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details